BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line …

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. BYSI ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2…#beyondspringinc #iit #plinabulin #beyondspring #etoposideplatinumep #ep #agent3 #pd1 #mdanderson #plinabulindc
Source: Reuters: Health - Category: Consumer Health News Source Type: news